1. Home
  2. |Insights
  3. |PODCAST: Court Limits EPA’s Ability to Delay Clean Air Act Regulation Without Rulemaking — C&M's Trump: The First Year Series

PODCAST: Court Limits EPA’s Ability to Delay Clean Air Act Regulation Without Rulemaking — C&M's Trump: The First Year Series

Client Alert | 1 min read | 07.06.17

In the latest podcast for Crowell & Moring’s “Trump: The First Year” series, Dan Wolff and Tom Lorenzen, both litigation partners in the firm’s Environment & Natural Resources Group and Administrative Law & Regulatory Practice, discuss the implications of a July 3 D.C. Circuit ruling invalidating EPA's 90-day administrative stay of the current oil and gas methane rule.

 Discussed in this 21-minute podcast: 

  • An overview of the Clean Air Council v. Pruitt decision.
  • The possible impacts of this decision on the administration’s stated goal of "deconstructing the administrative state."
  • Other possible mechanisms for halting rules in the short term without going through notice-and-comment rulemaking.
  • The practical implications of this ruling, and key takeaways for businesses.

Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...